MacroGenics Reports $150 Million Q4 Revenue, Net Loss of $67 Million

MacroGenics Inc. reported a total revenue of $150 million for 2024, a substantial increase from $58.7 million in 2023, largely due to milestone payments under the Incyte License Agreement. However, the company also experienced a net loss of $67 million, up from $9 million the previous year, attributed to rising research and development costs and a one-time gain on royalty monetization in 2023. Despite these challenges, MacroGenics is committed to advancing its clinical pipeline, including candidates like lorigerlimab and MGC026, with anticipated updates expected to influence future performance. Analysts, including Silvan Tuerkcan, have maintained a cautious outlook on the stock, assigning a Hold rating due to uncertainties surrounding ongoing projects and the company's valuation. MacroGenics ended 2024 with $201.7 million in cash and equivalents, which is expected to sustain operations into the latter half of 2026. Overall, while the financial growth is notable, the company faces significant hurdles in achieving profitability amidst continued investment in its development programs.